AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
21 nov. 2024 10h03 HE
|
AscellaHealth, LLC
2024 Deloitte Technology Fast 500™ Ranks AscellaHealth Number 154 with 753% Revenue Growth
AscellaHealth Releases Q3 2024 Specialty & Rare Pipeline Digest™: FDA-Approved Biosimilars Outpaces Cell and Gene Therapy Amid Complex Regulatory Challenges
22 oct. 2024 10h00 HE
|
AscellaHealth, LLC
BERWYN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today released its latest...
AscellaHealth Announces its Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
17 oct. 2024 06h00 HE
|
AscellaHealth, LLC; CHAPPER healthcare
AscellaHealth Announces Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
16 oct. 2024 10h00 HE
|
AscellaHealth, LLC
Optime Care Broadens Partnership with Rigel Pharmaceuticals for Expanded Commercial Distribution of TAVALISSE®
The cell and gene therapy bioassay services market is projected to be grow at an annualized growth rate of 30% by 2030, claims Roots Analysis
14 déc. 2021 09h00 HE
|
Roots Analysis
London, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Cell and Gene Therapy Bioassay Services Market, 2021-2030” report to its list of offerings. Bioassays are...
The cell and gene therapy contract research services market is anticipated to grow at annualized rate of CAGR 28.9% till 2030, claims Roots Analysis
13 juil. 2021 09h00 HE
|
Roots Analysis
London, July 13, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Cell and Gene Therapy CROs Market (2nd Edition), 2021-2030” report to its list of offerings. Despite the...